Lantern Pharma Flags $15B–$20B Market Opportunity Lantern Pharma projects a $15B–$20B aggregate market opportunity and warned funding needs are intensifying on Mar 30, 2026, increasing the probability of near-term financing actions.

Lantern Pharma Flags $15B–$20B Market Opportunity: Lantern Pharma projects a $15B–$20B aggregate market opportunity and warned funding needs are intensifying on Mar 30, 2026, increasing the probability of… 👈 Read full analysis #LanternPharma #MarketOpportunity #Biotech #Funding #Pharmaceuticals

Lantern Pharma FDA Clears Pediatric Trial Lantern Pharma won FDA clearance on Mar 27, 2026 to start a Phase 1 pediatric DIPG trial; DIPG carries median survival under 12 months and ~200–400 US cases/year.

Lantern Pharma FDA Clears Pediatric Trial: Lantern Pharma won FDA clearance on Mar 27, 2026 to start a Phase 1 pediatric DIPG trial; DIPG carries median survival under 12 months and ~200–400 US cases/year. 👈 Read full analysis #LanternPharma #FDAClearance #PediatricTrial #DIPG #ClinicalResearch